414 related articles for article (PubMed ID: 25779572)
1. In vitro drug combination studies of Letermovir (AIC246, MK-8228) with approved anti-human cytomegalovirus (HCMV) and anti-HIV compounds in inhibition of HCMV and HIV replication.
Wildum S; Zimmermann H; Lischka P
Antimicrob Agents Chemother; 2015; 59(6):3140-8. PubMed ID: 25779572
[TBL] [Abstract][Full Text] [Related]
2. Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure.
Goldner T; Hempel C; Ruebsamen-Schaeff H; Zimmermann H; Lischka P
Antimicrob Agents Chemother; 2014; 58(1):610-3. PubMed ID: 24189264
[TBL] [Abstract][Full Text] [Related]
3. Clinical development of letermovir and maribavir: Overview of human cytomegalovirus drug resistance.
Piret J; Boivin G
Antiviral Res; 2019 Mar; 163():91-105. PubMed ID: 30690043
[TBL] [Abstract][Full Text] [Related]
4. [Pharmacological and clinical effects of letermovir (Prevymis
Ogawa M; Eto T
Nihon Yakurigaku Zasshi; 2019; 153(4):192-198. PubMed ID: 30971660
[TBL] [Abstract][Full Text] [Related]
5. The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase.
Goldner T; Hewlett G; Ettischer N; Ruebsamen-Schaeff H; Zimmermann H; Lischka P
J Virol; 2011 Oct; 85(20):10884-93. PubMed ID: 21752907
[TBL] [Abstract][Full Text] [Related]
6. Phenotypic characterization of two naturally occurring human Cytomegalovirus sequence polymorphisms located in a distinct region of ORF UL56 known to be involved in in vitro resistance to letermovir.
Goldner T; Zimmermann H; Lischka P
Antiviral Res; 2015 Apr; 116():48-50. PubMed ID: 25637709
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246.
Lischka P; Hewlett G; Wunberg T; Baumeister J; Paulsen D; Goldner T; Ruebsamen-Schaeff H; Zimmermann H
Antimicrob Agents Chemother; 2010 Mar; 54(3):1290-7. PubMed ID: 20047911
[TBL] [Abstract][Full Text] [Related]
8. Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir (AIC246, MK 8228).
Lischka P; Michel D; Zimmermann H
J Infect Dis; 2016 Jan; 213(1):23-30. PubMed ID: 26113373
[TBL] [Abstract][Full Text] [Related]
9. In vitro evaluation of current and novel antivirals in combination against human cytomegalovirus.
O'Brien MS; Markovich KC; Selleseth D; DeVita AV; Sethna P; Gentry BG
Antiviral Res; 2018 Oct; 158():255-263. PubMed ID: 30153445
[TBL] [Abstract][Full Text] [Related]
10. In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products.
Komatsu TE; Hodowanec AC; Colberg-Poley AM; Pikis A; Singer ME; O'Rear JJ; Donaldson EF
Antiviral Res; 2019 Sep; 169():104549. PubMed ID: 31279814
[TBL] [Abstract][Full Text] [Related]
11. Artesunate demonstrates in vitro synergism with several antiviral agents against human cytomegalovirus.
Drouot E; Piret J; Boivin G
Antivir Ther; 2016; 21(6):535-539. PubMed ID: 26844400
[TBL] [Abstract][Full Text] [Related]
12. An overview of letermovir: a cytomegalovirus prophylactic option.
Gerna G; Lilleri D; Baldanti F
Expert Opin Pharmacother; 2019 Aug; 20(12):1429-1438. PubMed ID: 31282759
[No Abstract] [Full Text] [Related]
13. Letermovir for the management of cytomegalovirus infection.
Bowman LJ; Melaragno JI; Brennan DC
Expert Opin Investig Drugs; 2017 Feb; 26(2):235-241. PubMed ID: 27998189
[TBL] [Abstract][Full Text] [Related]
14. New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by
Chou S; Satterwhite LE; Ercolani RJ
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914965
[TBL] [Abstract][Full Text] [Related]
15. Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study.
Stoelben S; Arns W; Renders L; Hummel J; Mühlfeld A; Stangl M; Fischereder M; Gwinner W; Suwelack B; Witzke O; Dürr M; Beelen DW; Michel D; Lischka P; Zimmermann H; Rübsamen-Schaeff H; Budde K
Transpl Int; 2014 Jan; 27(1):77-86. PubMed ID: 24164420
[TBL] [Abstract][Full Text] [Related]
16. Impact of glycoprotein B genotype and naturally occurring ORF UL56 polymorphisms upon susceptibility of clinical human cytomegalovirus isolates to letermovir.
Lischka P; Zhang D; Holder D; Zimmermann H
Antiviral Res; 2016 Aug; 132():204-9. PubMed ID: 27345658
[TBL] [Abstract][Full Text] [Related]
17. The discovery and development of filociclovir for the prevention and treatment of human cytomegalovirus-related disease.
Hussein ITM; Brooks J; Bowlin TL
Antiviral Res; 2020 Apr; 176():104710. PubMed ID: 31940473
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic drug evaluation of letermovir prophylaxis for cytomegalovirus in hematopoietic stem cell transplantation.
Deleenheer B; Spriet I; Maertens J
Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1197-1207. PubMed ID: 30479172
[TBL] [Abstract][Full Text] [Related]
19. The antifungal drug isavuconazole inhibits the replication of human cytomegalovirus (HCMV) and acts synergistically with anti-HCMV drugs.
Mercorelli B; Celegato M; Luganini A; Gribaudo G; Lepesheva GI; Loregian A
Antiviral Res; 2021 May; 189():105062. PubMed ID: 33722615
[TBL] [Abstract][Full Text] [Related]
20. A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance.
Chou S
Antiviral Res; 2017 Dec; 148():1-4. PubMed ID: 29107686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
